tokyo and cambridge, mass., september 25, 2023 – eisai co., ltd. (headquarters: tokyo, ceo: haruo naito, “eisai”) and biogen inc. (nasdaq: biib, corporate headquarters: cambridge, massachusetts, ceo: christopher a. viehbacher, “biogen”) announced today that humanized anti- soluble aggregated amyloid-beta (aβ) monoclonal antibody “leqembi® intravenous infusion” (200 mg, 500mg, lecanemab) has been approved in japan as a treatment for slowing progression of mild cognitive impairment (mci) and mild dementia due to alzheimer’s disease (ad).
eisai’s affiliates in china are wholly-owned by eisai co., ltd. (eisai), a japanese multinational pharmaceutical company with strong r&d capabilities, as global headquarter in tokyo and headquarter of china in shanghai.
eisai has grown smoothly since entering the chinese market in the early 1990s and the total …